Northwire Canada EditionSaturday, October 17, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Netramark arranges $3.5-million private placement

AIAI · Price

Executive Summary

  • Netramark Holdings Inc. announced a non‑brokered private placement of up to 3.5 million units at $1.00 per unit, targeting gross proceeds of up to $3.5 million.
  • Each unit consists of one common share and half of a common‑share purchase warrant (full warrant exercisable at $1.35 per share for two years).
  • Net proceeds will be used for general working capital, further development and commercialization of the NetraAI platform, and to support existing and prospective biopharmaceutical collaborations.

Key Details

  • Offering Size: Up to 3.5 million units (each unit = 1 common share + ½ warrant).
  • Price per Unit: $1.00 → Maximum Gross Proceeds: $3.5 million.
  • Warrant Terms: One whole warrant (two half‑warrants) gives the holder the right to purchase one additional common share at an exercise price of $1.35 per share, exercisable for two years from closing.
  • Regulatory Basis: Offering relies on exemptions from prospectus requirements under Canadian securities laws; units and warrants subject to a statutory hold period of four months + one day.
  • Use of Proceeds: General working capital and corporate purposes, specifically:
  • Advancement and commercialization of the proprietary NetraAI platform.
  • Support for ongoing and prospective biopharmaceutical engagements.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Netramark Holdings Inc